Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
1996-12-02
2001-06-12
Ungar, Susan (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S040500, C435S040510, C435S040520
Reexamination Certificate
active
06245501
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to methods for studying tissue samples from a subject to predict the course of a tissue's tumor progression. In particular, the method determines the frequency of cells in a tissue which are undergoing abnormal cell division. More specifically, the invention relates to histochemical analysis of cell division in tissues.
2. Description of Related Art
The publications and other reference materials referred to herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference. For convenience, the reference materials are numerically referenced and grouped in the appended bibliography.
Cells often kill themselves in a process known as apoptosis or programmed cell death. Apoptosis is necessary for the body to properly function. Apoptosis is essential during embryonic development, differentiation, tissue remodeling, maturation of the immune system, tumor regression, and viral infection and is also involved in homeostasis. Faulty regulation of apoptosis may lie behind many diseases.
Both external stimuli and internal stimuli can induce apoptosis. For example, addition of glucocorticoid hormones to immature thymocytes, withdrawal of interleukin-2 from mature thymocytes, the removal of colony stimulating factors from haematopoietic precursors, and lack of adhesion in normal cells, may trigger apoptosis. Internal stimuli such as irreparable damage to genomic DNA or toxicity may also induce apoptosis. Cells undergoing apoptosis show a sequence of characteristic morphological changes including membrane budding, cytoplasmic shrinkage, and the condensation and margination of chuomatin. Frequently, apoptosis is associated with the activation of an endonuclease(s) that degrades the genomic DNA into large or oligonucleosomal fragments to yield a characteristic DNA ladder upon gel electrophoresis. The dying cells are broken into membrane-bound apoptotic bodies, which are phagocytosed by neighboring cells, avoiding a possible inflammatory response due to leakage of cell contents [reviewed in 1-6].
Apoptosis is often called programmed cell death because several gene products are involved in the regulation and execution of this process. An understanding of the set of genes involved in apoptosis comes from the studies on the nematode
Caenorhabditis elegans [
5]. These genes may fall into two groups: those that regulate the cell death program, and those that are involved in the execution phase of apoptosis. The nematode gene, ced-9, encodes a protein homologous to the mammalian Bcl-2 family of cell death regulators [7, 8].
The Bcl-2 family of apoptosis regulatory proteins consists of pro- and anti-apoptotic genes. In addition, the tumor suppressor genes p
53
and Rb which are involved in cell cycle regulation are also involved in regulating apoptosis. Loss of their functions may confer resistance in tumor cells to apoptosis-inducing agents such as chemicals and ionizing radiations. Therefore, tumor cells are capable of surviving current therapeutic modalities, although the exact mechanism of tumor cell resistance to apoptosis-inducers is not well understood at present [9]. For prognosis, it is critically important to detect the earliest signs of tumor cells which have escaped anti-tumor therapy and are likely to progress toward neoplasia. Early detection methods are therefore needed.
The genes involved in the execution phase of apoptosis include the nematode gene, nuc-1, that encodes endonuclease required for DNA fragmentation, and ced-3, that encodes a cysteine protease with homology to interleukin-1&bgr; converting enzyme (ICE)[10]. Recent studies have identified a protease, yama/CPP32&bgr;, as a mammalian homolog of CED-3 [11]. Other ICE-like family of enzymes include Nedd-2/Ich-1, Tx/Ich-2, and Mch-2 [reviewed in 6, 12].
Recent studies have shown that the morphological events characteristic of apoptosis can be induced in cytoplasts in the absence of a nucleus [13, 14]. Similarly, the cell nucleus was not required for cell-mediated granzyme- or fas-induced cell death pathways in target cells [15]. These and other studies have lead to the hypothesis that the gene products required for apoptosis are constitutively expressed in the cytoplasm [13, 16].
Although resistance of tumor cells to apoptosis inducers (e.g. chemotherapeutic agents and radiation) has been widely observed, the morphological changes of cells that escape anti-tumor therapy induced apoptosis and progress towards malignancy are unknown. There is a need to morphologically characterize the earliest stages of cells which escape induced apoptosis in order to predict the progression of the tumor cells in the patient toward malignancy or neoplasia.
DISCLOSURE OF THE INVENTION
The present invention overcomes the problem of being unable to identity the mechanism and early stages of cells that escape genotoxin-induced apoptotis. The invention is based upon the discovery of a form of cell division herein referred to as “endoapoptosis,” which represents the earliest known morphological changes characteristic of tumor cells which resist apoptosis induced by chemo-or radiation therapy. It will be understood that endoapoptosis can be considered a form of apoptosis but without resulting cell death. As a result of this discovery, the method of the invention predicts from the endoapoptotic appearance of tumor cells whether a tumor will progress toward malignancy.
The present invention provides a method of detecting if a subject with tumor cells is at increased risk of developing tumor progression. The method involves the step of determining the frequency of endoapoptosis in a sample of tumor tissue taken from the subject. The frequency of endoapoptosis in the tissue sample indicates whether the subject is at increased risk of developing tumor progression.
By determining the frequency of endoapoptosis in samples of tumor tissue obtained from a subject at various times either with or without treatment by chemicals and/or radiation, the invention further provides a method for monitoring the status of the tumor and the effectiveness of the treatment.
The above-discussed and many other features and attendant advantages of the present invention will become better understood by reference to the following detailed description of the invention taken in conjunction with the accompanying drawings.
REFERENCES:
Wyllie et al., Cell Death: The Significance of Apoptosis, Int. Rev. Cytol. 68:251 (1980).
Arends et al., Apoptosis: Mechanisms and Roles in Pathology, Int. Rev. Exp. Pathol. 32:223 (1991).
Ellis, Ronald et al., Mechanisms and Functions of Cell Death, Annu. Rev. Cell Biol. 7:663 (1991).
Raff, Martin C., Social Controls on Cell Survival and Cell Death, Nature 356:397 (1992).
White, Eileen, Life, Death and the Pursuit of Apoptosis, Genes Develop. 10:1 (1996).
Fisher, David E., Apoptosis in Cancer Therapy: Crossing the Threshold, Cell 78:539 (1994).
Martin, Seamus J., Protease Activation during Apoptosis: Death by a Thousand Cuts?, Cell 82:349 (1995).
Jacobson, Michael D., Programmed Cell Death and Bcl-2 Protection in the Absence of a Nucleus, EMBO J. 13(8):1899 (1994).
Schulze-Osthoff, Klaus et al., Cell Nucleus and DNA Fragmentation Are Not Required for Apoptosis, J. Cell Biol. 127:1 (1994).
Nakajima, H. et al., The Target Cell Nucleus is not Rquired for Cell-mediated Granzyme- or Fas-based Cytotoxicity, J. Exp. Med. 181:1905 (1995).
Caelles, C. et al., p-53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes, Nature 370:220 (1994).
Rajaraman, R. et al., A Novel Form of Apoptosis without Cell Death and its Role in Neoplasia, Mol. Biol. Cell 6: Suppl. 519a 1996.
R. Rajaraman et al., Apoptosis without Cell Death, Mol. Biol. Cell 5:Suppl 342a (1995).
Gorczyca W. et al., Detection of DNA Strand Breaks in Individual Apoptotic Cells by the in Situ Terminal Deo
Brotman Harris F.
Dalhousie University
Ungar Susan
LandOfFree
Method for cancer screening does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for cancer screening, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for cancer screening will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2480224